Perceptive Advisors - Q3 2013 holdings

$2.43 Billion is the total value of Perceptive Advisors's 214 reported holdings in Q3 2013. The portfolio turnover from Q2 2013 to Q3 2013 was 98.9% .

 Value Shares↓ Weighting
AEGR BuyAEGERION PHARMACEUTICALS INC$399,310,000
+76.4%
4,656,682
+30.3%
16.44%
-28.0%
SRPT BuySAREPTA THERAPEUTICS INC$226,641,000
+118.9%
23,044,138
+746.6%
9.33%
-10.6%
ONXX NewONYX PHARMACEUTICALS INC$138,902,0001,113,888
+100.0%
5.72%
ACRX BuyACELRX PHARMACEUTICALS INC$126,308,000
+172.1%
11,716,800
+133.9%
5.20%
+11.1%
TSRO BuyTESARO INC$117,278,000
+289.1%
3,027,288
+228.9%
4.83%
+58.9%
CELG BuyCELGENE CORP$112,402,000
+898.2%
729,238
+657.6%
4.63%
+307.7%
GILD BuyGILEAD SCIENCES INC$108,648,000
+168.8%
1,728,140
+119.2%
4.47%
+9.7%
NBIX BuyNEUROCRINE BIOSCIENCES INC$96,688,000
+42.2%
8,541,408
+68.1%
3.98%
-41.9%
RPRX BuyREPROS THERAPEUTICS INC$79,420,000
+2272.9%
2,963,466
+1533.4%
3.27%
+867.2%
VRTX BuyVERTEX PHARMACEUTICALS INC$68,554,000
+233.8%
904,190
+252.4%
2.82%
+36.3%
IBB NewISHARESput$60,700,000289,600
+100.0%
2.50%
QCOR BuyQUESTCOR PHARMACEUTICALS INC$43,656,000
+2177.3%
752,700
+1684.2%
1.80%
+831.1%
EXAS BuyEXACT SCIENCES CORP$41,260,000
+79.8%
3,496,628
+112.0%
1.70%
-26.6%
MYL NewMYLAN INC$35,140,000920,610
+100.0%
1.45%
CI BuyCIGNA CORPORATION$34,256,000
+163023.8%
445,696
+153588.3%
1.41%
+70400.0%
NEPT BuyNEPTUNE TECHNOLOGIES BIORESO$34,240,000
+94.5%
10,767,714
+98.6%
1.41%
-20.6%
ACAD BuyACADIA PHARMACEUTICALS INC$33,548,000
+154.4%
1,221,230
+68.1%
1.38%
+3.8%
SNTA BuySYNTA PHARMACEUTICALS CORP$30,052,000
+123.6%
4,762,472
+76.8%
1.24%
-8.7%
HNT NewHEALTH NET INC$28,770,000907,560
+100.0%
1.18%
ARNA NewARENA PHARMACEUTICALS INCput$26,962,0005,116,200
+100.0%
1.11%
PCRX NewPACIRA PHARMACEUTICALS INC$26,156,000544,068
+100.0%
1.08%
CSU BuyCAPITAL SR LIVING CORP$25,976,000
+21.9%
1,228,178
+37.8%
1.07%
-50.2%
F113PS BuyCOVIDIEN PLC$25,746,000
+506.9%
422,490
+525.9%
1.06%
+147.7%
SNTS BuySANTARUS INC$24,046,000
+82.8%
1,064,486
+70.3%
0.99%
-25.4%
CLVS BuyCLOVIS ONCOLOGY INC$23,676,000
+151.0%
389,402
+176.5%
0.98%
+2.5%
DYAX BuyDYAX CORP$23,226,000
+289.7%
3,385,824
+96.6%
0.96%
+59.1%
CTIC NewCELL THERAPEUTICS INC$22,676,00013,989,346
+100.0%
0.93%
ANAC BuyANACOR PHARMACEUTICALS INC$20,684,000
+534.9%
1,947,736
+234.2%
0.85%
+158.7%
IWM NewISHARESput$20,576,000193,000
+100.0%
0.85%
AMGN NewAMGEN INC$20,522,000183,350
+100.0%
0.84%
CHTP BuyCHELSEA THERAPEUTICS INTL LT$20,440,000
+90.8%
6,836,730
+46.8%
0.84%
-22.1%
SGMO NewSANGAMO BIOSCIENCES INC$20,246,0001,930,000
+100.0%
0.83%
WAG NewWALGREEN CO$20,214,000375,740
+100.0%
0.83%
P103PS BuyNPS PHARMACEUTICALS INC$19,452,000
+128.9%
611,524
+8.7%
0.80%
-6.5%
VNDA NewVANDA PHARMACEUTICALS INC$19,020,0001,737,000
+100.0%
0.78%
WCG BuyWELLCARE HEALTH PLANS INC$18,422,000
+87623.8%
264,162
+68513.5%
0.76%
+37800.0%
ISIS NewISIS PHARMACEUTICALS INC$14,476,000385,600
+100.0%
0.60%
ECYT BuyENDOCYTE INC$11,162,000
+1136.1%
837,430
+1117.1%
0.46%
+405.5%
AMRN NewAMARIN CORP PLCput$10,978,0001,737,000
+100.0%
0.45%
VNDA NewVANDA PHARMACEUTICALS INCcall$10,568,000965,200
+100.0%
0.44%
RPRX NewREPROS THERAPEUTICS INCcall$10,344,000386,000
+100.0%
0.43%
ITMN BuyINTERMUNE INC$9,228,000
+219.8%
600,000
+100.0%
0.38%
+30.6%
IMMU BuyIMMUNOMEDICS INC$9,146,000
+127.5%
1,475,010
+99.6%
0.38%
-6.9%
STML SellSTEMLINE THERAPEUTICS INC$8,172,000
-42.1%
180,416
-69.5%
0.34%
-76.4%
ARRY BuyARRAY BIOPHARMA INC$7,126,000
+7997.7%
1,145,740
+5830.3%
0.29%
+3155.6%
CNDO NewCORONADO BIOSCIENCES INCput$7,038,0001,003,800
+100.0%
0.29%
ATHX BuyATHERSYS INC$7,052,000
+22.1%
4,300,234
+23.6%
0.29%
-50.2%
ANIK NewANIKA THERAPEUTICS INC$6,884,000288,134
+100.0%
0.28%
INFI BuyINFINITY PHARMACEUTICALS INC$6,804,000
+275.3%
390,310
+248.7%
0.28%
+53.0%
NBIX NewNEUROCRINE BIOSCIENCES INCput$6,554,000579,000
+100.0%
0.27%
PSDV NewPSIVIDA CORP$6,346,0001,544,000
+100.0%
0.26%
VSTM NewVERASTEM INC$6,002,000482,130
+100.0%
0.25%
MZOR NewMAZOR ROBOTICS LTDsponsored ads$5,986,000354,156
+100.0%
0.25%
MDVN NewMEDIVATION INC$5,784,00096,500
+100.0%
0.24%
NBS NewNEOSTEM INC$5,670,000663,186
+100.0%
0.23%
CSBR BuyCHAMPIONS ONCOLOGY INC RSTD$5,452,000
+174.1%
3,116,488
+72.3%
0.22%
+11.4%
VVUS NewVIVUS INCput$5,384,000579,000
+100.0%
0.22%
SPNC SellSPECTRANETICS CORP$5,178,000
-17.9%
308,158
-8.8%
0.21%
-66.5%
ECYT NewENDOCYTE INCput$5,146,000386,000
+100.0%
0.21%
DXCM NewDEXCOM INC$4,094,000145,100
+100.0%
0.17%
KERX BuyKERYX BIOPHARMACEUTICALS INC$4,036,000
+979.1%
400,000
+700.0%
0.17%
+336.8%
MGCD BuyMGC DIAGNOSTICS CORP$3,820,000
+162.2%
348,898
+100.0%
0.16%
+6.8%
ANTH NewANTHERA PHARMACEUTICALS INC$3,468,000862,912
+100.0%
0.14%
CLDX NewCELLDEX THERAPEUTICS INC NEWcall$3,422,00096,600
+100.0%
0.14%
MNKD NewMANNKIND CORP$3,300,000579,000
+100.0%
0.14%
BCRX NewBIOCRYST PHARMACEUTICALS$2,774,000381,176
+100.0%
0.11%
MYGN NewMYRIAD GENETICS INCcall$2,740,000116,600
+100.0%
0.11%
MDGN BuyMEDGENICS INC$2,340,000
+310.5%
300,000
+100.0%
0.10%
+68.4%
TKMR BuyTEKMIRA PHARMACEUTICALS CORP$2,224,000
+78.8%
318,618
+18.0%
0.09%
-26.4%
VNDA NewVANDA PHARMACEUTICALS INCput$2,114,000193,000
+100.0%
0.09%
UPI BuyUROPLASTY INC$2,012,000
+225.0%
607,978
+103.3%
0.08%
+33.9%
ONTY NewONCOTHYREON INC$1,988,000965,000
+100.0%
0.08%
AMRN NewAMARIN CORP PLCcall$1,830,000289,600
+100.0%
0.08%
PGNX BuyPROGENICS PHARMACEUTICALS IN$1,698,000
+24.1%
338,136
+10.3%
0.07%
-49.3%
TBIO BuyTRANSGENOMIC INC$1,676,000
+89.8%
4,415,000
+100.0%
0.07%
-22.5%
AVNR NewAVANIR PHARMACEUTICALS INCput$1,632,000386,000
+100.0%
0.07%
RGEN NewREPLIGEN CORPput$1,514,000136,600
+100.0%
0.06%
NSPH NewNANOSPHERE INC$1,358,000679,000
+100.0%
0.06%
VICL NewVICAL INCcall$1,000,000800,000
+100.0%
0.04%
ASTX SellASTEX PHARMACEUTICALS INC$800,000
-88.2%
94,196
-94.3%
0.03%
-95.2%
STEM BuySTEMCELLS INC$778,000
+103.7%
463,200
+100.0%
0.03%
-17.9%
HTWR NewHEARTWARE INTL INC$732,00010,000
+100.0%
0.03%
ACST NewACASTI PHARMA INC$732,000308,772
+100.0%
0.03%
NAVB NewNAVIDEA BIOPHARMACEUTICALS Iput$618,000233,000
+100.0%
0.02%
XNPT NewXENOPORT INC$548,00096,500
+100.0%
0.02%
FURX NewFURIEX PHARMACEUTICALS INC$440,00010,000
+100.0%
0.02%
AZN NewASTRAZENECA PLCsponsored adr$280,0005,400
+100.0%
0.01%
OCR BuyOMNICARE INC$280,000
+1300.0%
5,050
+1088.2%
0.01%
+500.0%
CNC NewCENTENE CORP DEL$302,0004,710
+100.0%
0.01%
CYH NewCOMMUNITY HEALTH SYS INC NEW$284,0006,830
+100.0%
0.01%
LPNT NewLIFEPOINT HOSPITALS INC$280,0005,990
+100.0%
0.01%
HLS BuyHEALTHSOUTH CORP$288,000
+1340.0%
8,380
+1105.8%
0.01%
+500.0%
DVA NewDAVITA HEALTHCARE PARTNERS I$262,0004,620
+100.0%
0.01%
CVS NewCVS CAREMARK CORPORATION$262,0004,600
+100.0%
0.01%
HNGR BuyHANGER INC$276,000
+1280.0%
8,160
+1195.2%
0.01%
+450.0%
WOOF BuyVCA ANTECH INC$258,000
+1190.0%
9,430
+1109.0%
0.01%
+450.0%
AMSG BuyAMSURG CORP$272,000
+1260.0%
6,830
+1108.8%
0.01%
+450.0%
MD BuyMEDNAX INC$276,000
+1214.3%
2,750
+1122.2%
0.01%
+450.0%
ALR BuyALERE INC$270,000
+1250.0%
8,860
+1007.5%
0.01%
+450.0%
AET SellAETNA INC NEW$266,000
-96.3%
4,140
-96.3%
0.01%
-98.5%
MOH BuyMOLINA HEALTHCARE INC$256,000
+1180.0%
7,180
+1205.5%
0.01%
+450.0%
MGLN BuyMAGELLAN HEALTH SVCS INC$274,000
+1270.0%
4,580
+1154.8%
0.01%
+450.0%
KYTH NewKYTHERA BIOPHARMACEUTICALS I$252,0005,530
+100.0%
0.01%
ZLTQ NewZELTIQ AESTHETICS INC$248,00027,406
+100.0%
0.01%
CUTR SellCUTERA INC$220,000
-47.7%
24,800
-48.2%
0.01%
-78.6%
AXGN NewAXOGEN INC$40,0009,000
+100.0%
0.00%
CBMXW BuyCOMBIMATRIX CORPORATION*w exp 05/01/201$4,000
+300.0%
10,000
+100.0%
0.00%
ENDP ExitENDO HEALTH SOLUTIONS INC$0-530
-100.0%
-0.00%
DGX ExitQUEST DIAGNOSTICS INC$0-325
-100.0%
-0.00%
MDAS ExitMEDASSETS INC$0-1,150
-100.0%
-0.00%
V107SC ExitWELLPOINT INC$0-255
-100.0%
-0.00%
UNH ExitUNITEDHEALTH GROUP INC$0-315
-100.0%
-0.00%
HRC ExitHILL ROM HLDGS INC$0-590
-100.0%
-0.00%
HMA ExitHEALTH MGMT ASSOC INC NEWcl a$0-1,265
-100.0%
-0.00%
NAVB ExitNAVIDEA BIOPHARMACEUTICALS Iput$0-20,000
-100.0%
-0.01%
SNSS ExitSUNESIS PHARMACEUTICALS INC$0-58,010
-100.0%
-0.03%
EPZM ExitEPIZYME INC$0-18,000
-100.0%
-0.05%
LPDX ExitLIPOSCIENCE INC$0-82,292
-100.0%
-0.06%
BMR ExitBIOMED REALTY TRUST INC$0-50,000
-100.0%
-0.10%
CYCC ExitCYCLACEL PHARMACEUTICALS INC$0-350,000
-100.0%
-0.10%
AMRN ExitAMARIN CORP PLCput$0-193,000
-100.0%
-0.11%
VICL ExitVICAL INCcall$0-400,000
-100.0%
-0.13%
VPHM ExitVIROPHARMA INC$0-48,300
-100.0%
-0.14%
CEMP ExitCEMPRA INC$0-200,000
-100.0%
-0.16%
SGEN ExitSEATTLE GENETICS INCput$0-50,000
-100.0%
-0.16%
ANTH ExitANTHERA PHARMACEUTICALS INC$0-3,451,655
-100.0%
-0.16%
NBS ExitNEOSTEM INC$0-3,315,938
-100.0%
-0.19%
BDSI ExitBIODELIVERY SCIENCES INTL IN$0-477,600
-100.0%
-0.20%
QCOR ExitQUESTCOR PHARMACEUTICALS INCcall$0-50,000
-100.0%
-0.23%
GILD ExitGILEAD SCIENCES INCput$0-48,300
-100.0%
-0.25%
ARNA ExitARENA PHARMACEUTICALS INCput$0-393,200
-100.0%
-0.30%
NBIX ExitNEUROCRINE BIOSCIENCES INCput$0-300,000
-100.0%
-0.40%
SQNM ExitSEQUENOM INC$0-985,180
-100.0%
-0.42%
KMDA ExitKAMADA LTD$0-394,860
-100.0%
-0.44%
CRIS ExitCURIS INC$0-1,392,564
-100.0%
-0.45%
ELN ExitELAN PLCadr$0-483,000
-100.0%
-0.69%
OPTR ExitOPTIMER PHARMACEUTICALS INCput$0-496,500
-100.0%
-0.72%
SHPG ExitSHIRE PLCsponsored adr$0-80,800
-100.0%
-0.78%
SLXP ExitSALIX PHARMACEUTICALS INC$0-148,250
-100.0%
-0.99%
SRPT ExitSAREPTA THERAPEUTICS INCcall$0-275,000
-100.0%
-1.06%
HCA ExitHCA HOLDINGS INC$0-308,560
-100.0%
-1.12%
SRPT ExitSAREPTA THERAPEUTICS INCput$0-393,000
-100.0%
-1.51%
REGN ExitREGENERON PHARMACEUTICALS$0-139,310
-100.0%
-3.16%
IBB ExitISHARES TRput$0-269,400
-100.0%
-4.72%
BIIB ExitBIOGEN IDEC INC$0-231,282
-100.0%
-5.02%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2013-11-14
  • View 13F-HR/A filed 2013-11-14
Signatures

The EDGAR filing(s) were signed by:

About Perceptive Advisors

Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.

The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.

One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.

Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
NEUROCRINE BIOSCIENCES SHARES42Q3 202315.7%
AMICUS THERAPEUTICS SHARES39Q3 202314.0%
ALDEYRA THERAPEUTICS SHARES35Q3 20233.3%
QUOTIENT TECHNOLOGY INC34Q3 20222.7%
GLOBAL BLOOD THERAPEUTICS SHARES29Q3 20229.3%
ADMA BIOLOGICS SHARES29Q3 20231.4%
RETROPHIN SHARES28Q3 20205.5%
DBV TECHNOLOGIES SA-SPON ADR28Q3 20211.8%
VBI VACCINES SHARES27Q1 20232.8%
IOVANCE BIOTHERAPEUTICS INC26Q3 20239.1%

View Perceptive Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Perceptive Advisors Q3 2013 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
CHEMBIO DIAGNOSTICS, INC.Sold outMay 04, 202300.0%
VBI Vaccines Inc/BCApril 07, 202343,509,55316.7%
Landos Biopharma, Inc.March 30, 202314,869,91547.7%
REATA PHARMACEUTICALS INCMarch 07, 20232,083,7996.5%
AGILE THERAPEUTICS INCSold outFebruary 14, 202300.0%
ALBIREO PHARMA, INC.February 14, 20231,757,1608.5%
BELLUS Health Inc.February 14, 20238,891,0277.1%
CinCor Pharma, Inc.February 14, 20232,576,3255.9%
Coherus BioSciences, Inc.Sold outFebruary 14, 202300.0%
CONCERT PHARMACEUTICALS, INC.February 14, 20231,800,0003.6%

View Perceptive Advisors's complete significant-ownership history.

Latest filings
TypeFiled
SC 13D2024-03-20
SC 13G2024-03-14
SC 13G2024-03-11
SC 13G/A2024-03-06
SC 13D/A2024-03-01
SC 13G2024-03-01
SC 13D/A2024-02-29
13F-HR/A2024-02-26
SC 13G/A2024-02-23
42024-02-21

View Perceptive Advisors's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported has been restated
  • The reported has been amended

Export Perceptive Advisors's holdings